Darius Desai (@darius_desai) header
Darius Desai (@darius_desai) profile picture
Joined October 2015
Photo by Darius Desai (@darius_desai)Photo by Darius Desai (@darius_desai)Photo by Darius Desai (@darius_desai)Photo by Darius Desai (@darius_desai)
Less 🩸transfusions for hepatectomy Multicentre RCT 🇨🇦 by @ChamoGui 👥 446 pts Phlebotomy 🆚 usual care ⤵️🩸transfusion 16 to 8% NNT 11 😀 No change in complications Towards a new standard of care? 📝🔗 thelancet.com/journals/langa… @LancetGastroHep
10
25
2,228
New insights into G2 pancreatic neuroendocrine tumors! Subgrading G2a (Ki67 <10%) vs. G2b (10–20%) reveals distinct behaviors, with G2b showing metastatic potential akin to G3. Read more in @AnnSurgOncol: ow.ly/NVau50UmAWt #FeaturedArticle
2
3
623
Darius Desai retweeted
In which @BillKristol makes a direct appeal to the Trump-curious in his life in light of the debate. "Do you honestly believe this man can and should lead the country for the next four years?" thebulwark.com/p/the-beginni…
64
560
19
2,005
125,080
Value of Surgical Cytoreduction in Patients with Small Intestinal Neuroendocrine Tumors Metastatic to the Liver and Peritoneum ⁦@AnnSurgOncol⁩ link.springer.com/article/10…
1
7
2
38
2,946
Observation of small (≤2cm) panc NETs is widely accepted and becoming a standard. Maybe it is a little more nuanced... Should we take into account tumor grade as well as stage re resection? Small G2 pNETs are more likely than G1 to be N+ (15% vs. 3%). sciencedirect.com/science/ar…
8
26
74
6,693
Proud to be co-awarded this @TheVFoundation Translational Research Grant (co-sponsored by @MiamiDolphins) & work closely w/ the superbly talented @PeterHoseinMD. We will uncover an enigmatic mechanism of immunotherapy sensitivity in gHRD mutant #PancreaticCancer #pancsm Let’s go!
This quoted post is unavailable.
9
11
1
63
8,160
Most impressive data from #CheckMate9DW (frontline nivo/ipi in #HCC) is the median duration of response: 30.4 months❗️Reaffirms something we've seen time and time again⏩Anti-CTLA4 responses are the most durable
3
22
64
6,944
Darius Desai retweeted
🔥ctDNA dynamics in CRC with molecular residual disease 🔎Updated analysis from GALAXY, 2998 pts 👉ctDNA+ post-OP (14%) highly prognostic --> 2yr -OS 29% vs 86% 👉ctDNA clearence --> >90% DFS 🧐Supports ctDNA guided adj. treatment strategies @myESMO
2
44
1
109
8,652
🚨🚨🚨 Rectal Cancer Tweetorial!! Rectal cancer is a highly heterogeneous disease with rapid evolution in practice. Let's review current data to generate a pragmatic, patient-centric, approach to management! #GI24 #GIonc #RadOnc Thank you @ASCO for the opportunity!🙏🏽 1/
31
242
28
623
151,131
Trial 1 results #NEST Substantial & brisk responses to just one dose of BOT➕BAL immunotherapy. Join us on Tuesday January 23rd at 6 PM. @pashtoonkasi will discuss ASCO GI and Trial one results of #NEST. @ASCO #GI24
1
12
5
40
27,700
EMERALD-1 met primary endpoint of PFS. 👇🏼👇🏼👇🏼 @asco #GI24
9
2
22
6,360
Dr @jordanberlin5 going myth busters from #NET including radiosensitivity, Ki67 predicting biology and intervention randomization and role of SSA #GI23 #GIonc
3
8
25
3,139
Important secondary analysis of the OPRA trial with a median f/u of 4 years. This provides important details from a landmark study, and can help guide patient counseling. Of note, it's not broken down to compare induction TNT to consolidation TNT. My analysis is long-winded, and the target audience is surgeons who offer organ preservation to patients with rectal cancer: Patients with a cCR at restaging: 98% offered organ preservation/watch-and-wait (WW), of which 22% experienced local regrowth. Patients with a sustained cCR had a 5% rate of distant metastases. Of the local regrowths, 93% underwent salvage TME and 7% underwent salvage local excision. For these patients, 33% developed recurrence (4% local, 22% distant, and 7% local+distant). _______________________________________ Patients with a near-complete CR at restaging: 20 (17.5%) went straight to surgery, of which only 3 (16%) had a pathologic CR (pCR). Recurrence after upfront TME for near-cCR was 30% (15% local, 10% distant, 5% local+distant). These numbers were small (n=3 for local recurrence) and should be interpreted with caution. Of the remaining 94 patients (82.5%) who underwent WW, 48 (51%) developed local regrowth. Salvage TME was performed in 34 patients (71% compared to 93% for cCRs). 2 of 34 TMEs (6%) had a pCR. For patients with a near-cCR who developed regrowth after WW, 33% developed recurrence (4% local, 21% distant, 8% local+distant). Of the 46 patients (40%) with a near-cCR who remained in the WW program, 13% developed distant metastases (compared to 5% for cCRs). ______________________________________ Patients with an incomplete response at restaging: 88% were offered upfront TME, of which 4/51 (8%) had a pCR. For ICR and upfront TME, recurrence rate was 35% (3.5% local, 21% distant, 10.5% local+distant). 8 patients with incomplete response were still enrolled in WW for different reasons, of which 5/8 (63%) developed local regrowth. All 5 underwent TME, and the local recurrence was 20% (1/5). Of the 3/8 that remained in WW without regrowth, 2/3 (66%) developed lung metastases. _______________________________________ Overall, the 3-year organ preservation rate was 77% for cCRs and 40% for near-cCRs. The median time to TME for near-cCRs was 1 year. 3-year DFS was 88% for cCR, 69% for near-cCR, and 56% for incomplete response. _____________________________ For patient counseling purposes: Of the 123 patients with a cCR who were offered WW, the local recurrence rate was 22% (0f which 93% underwent salvage TME) and the rate of distant metastasis was 10.5%. Of the 94 patients with a near-cCR who were offered WW, local recurrence rate was 51% (of which 71% underwent salvage TME) and the rate of distant metastasis was 15%. Of the 57 patients with incomplete response who were offered upfront TME, local recurrence was 14% and the rate of distant metastasis was 32%. @JohnRTMonsonMD @R_Perez_MD @ianmpaquette @JonVogel7 @jendavidsmd @KyleCologne @debby_keller @juliomayol @Neil_J_Smart @FergaljFleming @ScottRSteeleMD @JISBMD
This Post is from a suspended account. Learn more
4
44
6
96
30,455
This @AnnSurgOncol #FeaturedArticle found that combined hepatic artery infusion and modern systemic therapy in chemotherapy-naive patients with unresectable CRLM resulted in durable and substantial response in a large proportion of patients. 📃: ow.ly/J98R50Q6A7Y
2
3
1,416
Effect of #AnastomoticLeak on Long-Term Survival After #Esophagectomy : Multivariate Meta-analysis and Restricted Mean Survival Times Examination @AlbertoAiolfi rdcu.be/dqwBP
1
7
7
1,793
PUBLISHED: #CirculatingTumorCells are an Independent Risk Factor for Poor Prognosis in Patients with #GallbladderAdenocarcinoma. rdcu.be/dlqiN @SocSurgOnc
11
3
19
6,052